Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease (TED) through a phase 3 trial and hopefully on to commercialization. | Sling ...

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead Sciences’ CEO ...

After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program ...

To keep the resources flowing to this new strategy, Sionna is reducing its headcount by around 46%, including the departure ...

A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...

Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in ...

Axoltis Pharma announced today that its phase 2 trial for amyotrophic lateral sclerosis (ALS) has missed its primary endpoint ...

Cellectis is also switching over to in vivo, channelling its resources to two preclinical candidates: HEAL-101, an in vivo ...

Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s Afib device Laminar program for an undisclosed price. The Laminar device focuses on a catheter-based left ...